Neuraxis, INC
No enriched coverage for $NRXS in the last 7 days.
NeurAxis, Inc. (NRXS) expanded its medical policy coverage to include 26M more members, bringing its total to over 147M, after a deal with a major national insurer. This follows the addition of its PENFS (IB-Stim) treatment.
Neuraxis declared a stock dividend for its Series B Preferred, converting accrued Q3 2026 dividends into common shares. Approximately 81,339 common shares will be issued, with fractional shares paid in cash at $2.38 per share. The dividend is payable on October 30, 2026, to holders of record as of October 26, 2026, according to the company.
Neuraxis, INC (NRXS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 14, 2026, the Board of Directors of Neuraxis, Inc. (the “ Company ”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for the third quart
Recent NRXS coverage spans financial news, corporate actions and insider activity.
In the last 30 days, NRXS insiders filed 3 SEC Form 4 transactions — 3 purchases ($12K) and no sales. The most active reporter was Henrichs Timothy Robert, Chief Financial Officer, with 1 filing.
The new insurer coverage expands NeurAxis' addressable market and could boost revenue growth.
The conversion will slightly increase share count, creating modest dilution and modest downward pressure on the stock.
New dividend issuance will dilute existing shareholders and may cause modest downward pressure on the stock.
Insider buying may signal confidence and could support short-term price upside.
Small insider purchase may create modest bullish pressure.
AlphAI scores every news story that mentions NRXS with an AI model for sentiment and relevance, and aggregates insider trades from Neuraxis, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
NeurAxis, Inc. (NRXS) expanded its medical policy coverage to include 26M more members, bringing its total to over 147M, after a deal with a major national insurer. This follows the addition of its PENFS (IB-Stim) treatment.
1 min readNeuraxis declared a stock dividend for its Series B Preferred, converting accrued Q3 2026 dividends into common shares. Approximately 81,339 common shares will be issued, with fractional shares paid in cash at $2.38 per share. The dividend is payable on October 30, 2026, to holders of record as of October 26, 2026, according to the company.
1 min readNeuraxis, INC (NRXS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 14, 2026, the Board of Directors of Neuraxis, Inc. (the “ Company ”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for the third quart
1 min readNeuraxis CRO Thomas Carrico bought 328 shares at $4.84 each, totaling $1,587. He now holds 199,673 shares. NRXS shares are up 40% since his purchase and 116% over the past year. Neuraxis reported Q2 2026 revenue growth of 116% to $1.928 million but a wider loss of $0.19 per share. The company's gross margins improved.
1 min readNeuraxis CFO Timothy Henrichs bought 1,937 shares of Neuraxis (NRXS) stock at $4.84 per share, totaling $9,375. The company reported a 116% revenue increase to $1.928M in Q2 2026, but a wider loss of $0.19 per share. NRXS shares are up 40% since the purchase, with a 116% return over the past year.
2 min readCarrico Brian Allen (Chief Executive Officer) purchased 268 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readCarrico Thomas Joeseph (CRO, CCO, CPO) purchased 328 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readHenrichs Timothy Robert (Chief Financial Officer) purchased 1,937 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readDataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readNeurAxis (NRXS) shares rose 25% to $7.15 after announcing new medical coverage from a major insurer for its Percutaneous Electrical Nerve Field Stimulation, affecting 18 million members. The stock opened at $6.14 and peaked at $7.30.
1 min read
